Licensing analysis: big deals bolster biotech
PD-(L)1 x VEGF bispecifics prove a big draw.
Regeneron enters the T-cell engager arena
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
EHA 2025 – J&J claims an extramedullary edge
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.
Akeso looks early in small-cell lung cancer
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
ASCO 2025 – BioNTech shows promise in mesothelioma
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
ASCO 2025 – J&J challenges its own multiple myeloma T-cell engagers
Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.
ASCO 2025 – Amgen gets one over on Zai Lab
Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.
ASCO 2025 – J&J takes another prostate cancer shot
The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.
